C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human ...

Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that exceeded analyst expectations, with the gene editing company posting a loss of $0.06 per ...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinic ...

Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the ...

Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

TD Cowen 46th Annual Health Care Conference March 3, 2026 3:10 PM ESTCompany ParticipantsEric BrownGiacomo Salvadore - Chief ...

Michael Nedelcovych TD Cowen, Research Division. Good afternoon, everyone. Welcome once again to TD Cowen's 46th Annual Healthcare Conference, and welcome to the Takeda session. W ...

A case study shows how sickle cell retinopathy may be the first clinical manifestation of underlying hemoglobinopathy.

Heterozygous COL17A1 variants are a frequent cause of amelogenesis imperfecta 18 November 2023 MGRN1 is linked to recessive heart and laterality defects: the first genotype-phenotype report in humans ...